Blastic plasmacytoid DC neoplasm (BPDCN) is a rare haematopoietic malignancy with an aggressive behaviour. We evaluated five patients allografted as consolidative treatment with an unrelated donor in first or subsequent remission. Four patients received a reduced intensity-conditioning regimen because of age or co-morbidities. As the stem cell sources, two umbilical cord blood-(UCB), two PBSC-and one BM graft were used. No GVHD was observed in the patients who received a UCB graft. However, both developed a post-transplant-associated lymphoproliferative disease. So far, only one patient has experienced relapse and was consecutively treated by escalated donor lymphocyte infusions (DLI). A potent graft-versus-leukaemia (GVL) effect was induced leading to a 17-month-long CR. Four patients are still in ongoing CR with median disease-free and overall survivals of 17 and 21 months. Thus, allogeneic SCT in BPDCN offers a potential curative option for patients with a compatible donor. UCB is an attractive alternative as a stem cell source. For relapsing patients, DLI can exert a powerful GVL effect.
INTRODUCTION
Blastic plasmacytoid DC neoplasm (BPDCN) is a rare, clinically aggressive haematopoietic malignancy typically involving skin, BM and lymph nodes. It had primarily been classified as blastic natural-killer (NK) cell lymphoma or CD4 þ CD56 þ haematodermic neoplasm, but findings of a myeloid origin have led to a change in terminology by the 2008 WHO classification. [1] [2] [3] In general, elderly patients are affected, but the disease also occurs in patients younger than 50 years and even in children. [4] [5] [6] In three large retrospective series of BPDCN, a clear male predominance was reported, suggesting that males are affected almost three times more often than females. [5] [6] [7] Commonly, BPDCN presents with a highly aggressive behaviour and the prognosis is generally poor. The median overall survival ranges from 12 to 14 months even though high response rates (80-90%) to initial multiagent chemotherapy are reported. The underlying reason is a high relapse rate within 9-11 months. 6, 7 Durable responses have only been achieved with allo-SCT even in elderly patients. [5] [6] [7] [8] For patients lacking a suitable matched donor, umbilical cord blood (UCB) may also be a viable source of stem cells. 9 Corroborating these findings, we report five cases of BPDCN consolidated with allo-SCT as part of the first-or secondline treatment, including two patients receiving UCB as stem cell source.
PATIENTS AND METHODS
Between 2009 and 2011, five patients with BPDCN were treated at our centre. In all cases, diagnosis was proven by histological examination of skin-or BM biopsy showing characteristic diffuse infiltrates of mediumsized blastoid cells expressing a typical immunohistochemical profile (positivity for CD4, CD56, CD123 and TCL-1, and negativity for B-, T-cell and myeloid markers).
Treatment plan
In the absence of standardized treatment protocols for this entity, different lymphoma-like induction treatment protocols were used (Table 1) . In three patients, a combination therapy consisting of CY 2 g/m 2 once daily i.v. on day 1 and 2 (total dose 4 g/m 2 ), liposomal doxorubicin 30 mg/m 2 i.v. once daily on day 1, vinorelbine 30 mg i.v. once daily on day 1 and prednisone 25 mg once daily p.o. for five consecutive days (total dose 500 mg) was applied (Hyper-CCVP). 10 One patient received a CHOP regimen combined with prophylactic intrathecal liposomal cytarabine and one hyper-CVAD as induction treatment. 11, 12 Depending on each treatment regimen, up to six cycles were applied. All patients were planned for consolidating allo-SCT as part of the first-line regimen. All patients gave written informed consent for each individual treatment. Conditioning regimens were individually chosen, depending on the patient's response to prior treatment, age and comorbidities.
A myeloablative conditioning regimen with fractionated TBI (fTBI) 2 Gy twice daily for three consecutive days (total dose 12 Gy), followed by highdose CY 60 mg/kg i.v. once daily on two consecutive days (total dose 120 mg/kg) (fTBI/CY) was used in one patient. Owing to age and comorbidities, a reduced intensity conditioning (RIC) regimen consisting of fludarabine 30 mg/m 2 i.v. once daily for five consecutive days (total dose 150 mg/m 2 ) and melphalan 140 mg/m 2 i.v. once daily on day 2 (Flu/Mel) was employed in two patients. In the remaining two patients receiving a UCB graft, a combination therapy consisting of fludarabine 30 mg/m 2 on six consecutive days i.v. (total dose 180 mg/m 2 ), CY 50 mg/kg i.v. once daily on day À 3 and fTBI 200 cGy twice daily (total dose 400 cGy) on day 2 (Flu/ Cy/fTBI) was administered. During conditioning, anti-thymocyte globulin 5 mg/kg on four consecutive days (total dose 20 mg/kg) (ATG Fresenius Biotech, Munich, Germany) was added. Patients received either peripheral blood stem cells (n ¼ 2) or BM (n ¼ 1) from a well-matched high-resolution genotyped unrelated donor (human leukocyte antigen (HLA)) (match X10/10) or-if no compatible donor was available-a partially (4/6 Ag) matched UCB graft transplantation. GVHD prophylaxis consisted of cyclosporine and MTX (n ¼ 3) or CYA and mycophenolate mofetil (n ¼ 2).
RESULTS

Patient characteristics
Our cohort consisted of three male and two female patients with a median age at diagnosis of 56 (range: 38-64) years. At initial diagnosis, patients presented with solitary or multiple skin lesions (n ¼ 4), BM-(n ¼ 3) or lymph node involvement (n ¼ 1) and in one patient BDCN-specific blasts were detected in the peripheral blood (Table 1) .
First-line Treatment
Initial response to induction chemotherapy was high with CR in all patients.
Unfortunately, before proceeding to consolidative allo-SCT, two patients (#2 and #4) relapsed within 4 and 2 months after completion of induction chemotherapy and were salvaged with two subsequent cycles of their initial induction therapy (Hyper-CCVP in #2, and CHOP in #4).
Allo-SCT All patients experienced a stable tri-linear engraftment and full donor chimerism was established after 28 days. Using a RIC conditioning regimen, patients #1 and #5 proceeded to allo-SCT in first CR with PBSC (#1) and BM (#5) as donor source and are still experiencing ongoing CR 12 and 25 months after SCT, respectively.
Patient #2 achieved a second CR, following salvage therapy with two cycles of hyper-CCVP and underwent allo-SCT with UCB as the stem cell source after Cy/Flu/fTBI as preparative regimen. The post-transplant period was uneventful; however, 12 months after UCB transplantation, he presented with a stenosing, ulcerative tumour of the transverse colon with liver lesions representing an EBV-positive post-transplant-related lymph proliferative disease with classical Hodgkin's lymphoma phenotype (CD30 positive, CD20 negative), but with no evidence of BPDCNspecific relapse. Therapy with brentuximab-vedotin (1.8 mg/kg) every 3 weeks was initiated. Similarly, patient #3 underwent allo-SCT with UCB in first CR after Cy/Flu/fTBI conditioning and remained disease free for 16 months. However, 10 months after UBCT, she presented with new skin and pulmonary lesions. A biopsy from both sites revealed an EBV positive aggressive plasmoblastic lymphoma, classified as post-transplant-related lymphoproliferative disease. Four cycles of rituximab monotherapy, followed by four further consolidation cycles resulted in an ongoing CR lasting 5 months. 13 Patient #4 relapsed immediately before proceeding to transplant and was offered two further CHOP cycles combined with prophylactic intrathecal liposomal cytarabine as salvage and received an allo-SCT after myeloablative conditioning (Cy, fTBI) in PR. SCT converted the PR to a stable CR phenotype. Unfortunately, after 8 months, a cutaneous relapse was diagnosed, followed by meningeal involvement by BPDC-specific blasts. Intrathecal chemotherapy with liposomal cytarabine (50 mg once daily) every 2 weeks for six cycles was able to clear the central nervous system and entirely reverse the neurological symptoms (mainly visual disturbances). Treatment with escalated doses of donor lymphocyte infusions (DLI, four times, starting with 3 Â 10 6 , 1 Â 10 7 , 3 Â 10 7 , 1 Â 10 8 CD3 þ cells/kg) exerted a potent graftversus-leukaemia effect and led to a second CR, but was accompanied by a severe chronic GVHD overlap syndrome involving the skin and gastrointestinal (GI) tract. Initial treatment with steroids and mycophenolate mofetil was ineffective and thus, third-line treatment with extracorporeal photopheresis was established leading to a partial response. However, one year later, Unrelated SCT in BPDCN M Unteregger et al a third isolated central nervous system relapse occurred and, subsequently, the patient succumbed to disease progression 39 months after diagnosis.
DISCUSSION BPDCN is a rare malignancy derived from plasmacytoid dendritic cells, exhibiting a highly aggressive clinical behaviour and is characterised by rapid progression. 1-4 BPDCN displays tropism for the skin, but also frequently involves BM, lymph nodes or peripheral blood and/or central nervous system. 5, 9 The diagnosis requires histological characterisation of tumour cells typically presenting as CD4-positive/CD56-positive/CD123-positive phenotype. [1] [2] [3] [4] [5] The best initial induction therapy remains undefined. Although a high-response rate can be obtained with 'lymphoma-like' regimens, several reports suggest a higher response rate with more intensive treatment protocols, according to 'acute leukemia'-like regimens. 7 Especially in children, treatment with ALL-like regimens appears to be effective in disease control, even without subsequent allo-SCT. 4 Lymphoma treatment strategies like hyper-CVAD or CHOP or AMLlike protocols 6, 7 are commonly used resulting in a high proportion of short-term remissions. [6] [7] [8] Owing to high-relapse rates even after allo-SCT, effective post-remission strategies are warranted. In the literature, only a few publications report on patients treated with AML or lymphoma-based chemotherapy, followed by autologous or allo-SCT. [6] [7] [8] [9] 11, 14, 15 The most complete review by Reimer et al.
7
includes 91 patients, three of whom were given autologous transplants in first CR and four of whom received an allogeneic SCT in first CR; whereas all patients undergoing autologous SCT relapsed, three of four recipients of allogeneic SCT remained in remission with a follow-up past 5 years. Three more patients received the allo-SCT in second or subsequent remission and all of them succumbed to disease recurrence or toxicity. However, as a myeloablative conditioning protocol was applied, this procedure is restricted to younger eligible patients. Further, a retrospective French registry analysis of 47 BPDCN patients, nine of whom were treated by allo-SCT, largely confirmed the superiority of the allogeneic transplant procedure compared with a non-transplant treatment strategy (overall survival 31.3 vs 12.8 months, P ¼ 0.0018). 6 To overcome the toxicity of a myeloablative conditioning protocol associated with high procedure-related mortality, Dietrich et al. 8 first reported a RIC allo-SCT treatment approach, including three patients after salvage therapy for first relapse, resulting in long-term remission in one patient. 8 Interestingly, this patient was the only one in their series suffering from extensive chronic GVHD, which suggests a clinically significant graft-versus-leukaemia effect operating in BPDCN. 8 Taken together the accumulated data suggest that allo-SCT in first remission could potentially improve the otherwise fatal prognosis of BPDCN.
For this reason, we followed a treatment algorithm implementing allogeneic SCT early after achieving first remission in eligible patients. Out of five patients, four are still alive and disease free after a median observational period of 16 months (range 7-27). Although the follow-up is still short, one has to consider that the median overall survival in BPDCN is only 13 months. 7 So far, only one patient (#4) succumbed to disease recurrence. Although a myeloablative regimen (fTBI,Cy) was employed and prophylactic intrathecal cytarabine was instilled, this patient developed a cutaneous and meningeal relapse 8 months after transplantation. However, with escalated doses of DLI and cerebrospinal fluid (CSF)-directed therapy with repetitive liposomal cytarabine instillations, a second CR was achieved, although at the expense of a severe steroid refractory GVHD. The intrathecal instillation of cytarabine led to a complete clearance of blasts after two doses with complete resolution of neurological symptoms. It has been postulated that the immunological effect of graft-versusleukaemia induced by the allogeneic graft is considered to reduce the incidence of relapse after transplantation. Kaloyannidis et al. 15 reported a powerful graft-versus-leukaemia effect in BPDCN after DLI. We confirm these findings, as our patient attained a second CR after DLI without preceding chemotherapy, but this therapeutic success was linked to the emergence of severe GVHD after a maximum DLI dose of 1 Â 10 8 CD3 þ cells/kg. However, although extensive GVHD was present, 1 year later an isolated central nervous system relapse occurred and the patient died because of disease progression 39 months after diagnosis.
In the absence of any compatible donors, two patients (#2 and #3) underwent umbilical cord graft transplantation with a partially (4 out of 6 Ag) matched graft. The main practical advantages of using cord blood as an alternative source of stem cells are the fast availability, the reduced likelihood of transmitting infectious diseases and the reduced incidence of acute and chronic GVHD. 16, 17 Duff et al. 11 reported the first successful cord blood transplantation in a young female patient with BPDCN after myeloablative conditioning. Similarly, the two patients in our cohort were able to be successfully consolidated by umbilical cord graft transplantation and are still disease-free after a period of 13 and 18 months. However, after 9 and 12 months, both patients developed an EBV-related post-transplant lymphoproliferative disorder-a well-known serious complication after UCB transplants, particularly, when using ATG in the preparative regimen. 18 Such patients might benefit from a close EBV monitoring and a pre-emptive approach using targeted therapy with rituximab in CD 20-positive EBV-associated post-transplant-related lymph proliferative disease. 13 Although only myeloablative allogeneic transplantation in first remission showed superiority in overall survival compared with all other treatment regimens in younger patients, this treatment option is confined to a minority of fit patients. However, BPDCN primarily affects the elderly with a mean age at diagnosis of 67.1 years. 7 To overcome the problem of a high transplant-related mortality by a myeloablative SCT, Dietrich et al. 8 employed a moderately RIC regimen in a small case series of four elderly patients (median age 67 years) resulting in a prolonged disease-free survival in two of them. Analogous to our series, four patients with a median age of 58 years were offered a RIC transplant in first (n ¼ 3) or second (n ¼ 1) CR, which resulted in a DFS and OS of 17 (range 13 to 27) and 22 (range 19 to 30) months, respectively. All patients are still alive and relapse free. Remission status at the time of transplantation seems to be of paramount importance, as all BPDCN patients transplanted in CR with an unrelated donor using RIC conditioning are still free of relapse.
In conclusion, this retrospective single centre study comprising five patients demonstrates that allo-SCT for BPDCN employing a RIC regimen in elderly patients is feasible and results in longterm disease control. Achieving CR before allo-SCT in this series was of particular importance for the outcome and may offer a potential curative option for patients with a compatible donor. For patients lacking a suitable donor, UCB is an attractive alternative as a graft source. Relapsing patients might be offered DLI that are capable of exerting a powerful graft-versus-leukaemia effect inducing long lasting remission. Although the follow-up time is still limited and results have to be confirmed within prospective clinical studies, the remission duration achieved by the allo-SCT approach appears to be clearly superior to non-transplant strategies and strongly argues for the early incorpoartion of allo-SCT into the treatment algorithm of patients with BPDCN.
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